SoftOx Solutions finalizes share capital increase from private placement

SoftOx Solutions AS has officially registered its new share capital with the Norwegian Register of Business Enterprises, following the completion of a private placement. This capital increase, initially resolved by the board on September 25, 2025, involved a private placement of NOK 6,000,000. The financing was secured through an existing facility with investment fund Long State Investments Limited.

With the registration complete, the company's new share capital stands at NOK 46,308,339.88, distributed across 2,315,416,994 shares, each with a par value of NOK 0.02. Further details regarding the underlying financing facility were previously disclosed in the company's stock exchange release dated September 14, 2025.

SoftOx Solutions AS, listed on Euronext Growth Oslo, is a clinical-stage pharmaceutical company. It specializes in developing pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi, leveraging extensive research and development partnerships with leading Nordic research institutions.